PEComa

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Section editor
Elizabethdavis2.jpg
Elizabeth J. Davis, MD
Vanderbilt University
Nashville, TN

Social-twitter-icon.png ejdavis25

Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.

1 regimens on this page
1 variants on this page


All lines of therapy

nab-Sirolimus monotherapy

back to top

Regimen

FDA-recommended dose
Study Years of enrollment Evidence
Wagner et al. 2021 (AMPECT) 2016-2018 Phase 2 (RT)

Targeted therapy

21-day cycles

References

  1. AMPECT: Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Grigorian B, Schmid AN, Hou S, Harris K, Kwiatkowski DJ, Desai NP, Dickson MA. nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. J Clin Oncol. 2021 Nov 20;39(33):3660-3670. Epub 2021 Oct 12. link to original article contains verified protocol link to PMC article PubMed NCT02494570